We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+14.47%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.35B
AUM Growth
+$9.88M
Cap. Flow
+$151M
Cap. Flow %
11.19%
Top 10 Hldgs %
48.37%
Holding
65
New
13
Increased
7
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
TECX
Tectonic Therapeutic
TECX
+$45.3M
2
AUTL
Autolus Therapeutics
AUTL
+$40.3M
3
KZR
Kezar Life Sciences
KZR
+$27.4M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$26.1M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$22.2M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$81.7M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$23.7M
3
YARW
Yarrow Bioscience, Inc. Common Stock
YARW
+$12.7M
4
CLSD
Clearside Biomedical
CLSD
+$7.65M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$7.01M

Sector Composition

Rank Sector Weight
1 Healthcare 88.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
51
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.44M 0.25%
573,208
– –
INDP icon
52
Indaptus Therapeutics
INDP
$172M
$3.4M 0.25%
345
– –
MRNS
53
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.38M 0.25%
119,528
– –
SRRK icon
54
Scholar Rock
SRRK
$5.67B
$3.28M 0.24%
+210,078
New +$3.94M
MGTX icon
55
MeiraGTx Holdings
MGTX
$1.09B
$2.73M 0.2%
+238,580
New +$3.2M
PTGX icon
56
Protagonist Therapeutics
PTGX
$8.79B
$2.57M 0.19%
382,139
– –
ONSIW
57
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$20K ﹤0.01%
416,666
– –
CLRBW
58
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$10K ﹤0.01%
52,999
– –
ANAB icon
59
CALL
AnaptysBio
ANAB
$1.58B
– –
-129,400
Closed -$13.5M
EOLS icon
60
Evolus
EOLS
$385M
– –
-342,400
Closed -$3.09M
YARW
61
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
– –
-94
Closed -$12.7M
JNCE
62
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-82,988
Closed -$1.85M
KDMN
63
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-1,648,432
Closed -$7.01M
ONSIZ
64
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
– –
-416,666
Closed -$18K
AVXS
65
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-192,094
Closed -$23.7M
1 2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Cormorant Asset Management held 65 positions worth $1.35B, up 0.74% from $1.34B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Cormorant Asset Management deployed $151M of net new capital in Q2 2018, opening 13 new positions and adding to 7 existing holdings. Its largest new stake was Tectonic Therapeutic: 125,649 shares worth $43.1M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 83% a quarter earlier.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $81.7M trimmed.

  • Cormorant Asset Management's largest Q2 2018 buy was Tectonic Therapeutic: 125,649 shares worth $43.1M.
  • Cormorant Asset Management added most to Arena Pharmaceuticals Inc in Q2 2018, an estimated $14M increase.
  • Cormorant Asset Management's biggest Q2 2018 reduction was Nektar Therapeutics, cutting an estimated $81.7M.
  • Cormorant Asset Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $23.7M.
  • Cormorant Asset Management's ten largest holdings make up 48% of its $1.35B portfolio in Q2 2018.
  • Cormorant Asset Management opened 13 new positions and closed 7 in Q2 2018.
  • Cormorant Asset Management's portfolio value rose 0.74% quarter-over-quarter to $1.35B.

Based on Cormorant Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.